Scottish health tech firm Emblation has unveiled its new £4 million state-of-the-art headquarters located in Stirling, marking a significant milestone in the firm’s global expansion journey.
Emblation, the Alloa-based health-tech innovator is undertaking a rigorous clinical trial which could transform the fortunes of its microwave treatments in the US.
Sir Tom Hunter, through West Coast Capital (WCC), the investment arm of the Hunter family, has made a multi-million-pound contribution to Ellipses Pharma, an innovative cancer drug venture.
St Andrews-based biotech firm Pneumagen has secured £8 million in financing from existing and new investors to support the continued Phase 2 development of Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs).
German science and technology giant, Merck, has announced plans to invest €35 million (£30m) in the expansion of its biosafety testing capabilities in Glasgow and Stirling.
Edinburgh-based Lentitek Ltd, a developer of pioneering manufacturing technologies enabling economic delivery of advanced cell and gene therapies, announced today that it has secured £250,000 ($300,000 USD) in seed investment. This investment will be deployed to further advance its technology and commence initial commercial trials.
The Sustainable Aquaculture Innovation Centre (SAIC) has announced support for a further six innovation projects valued at £2.5 million, taking its total investment in research and development initiatives to 100 projects.